-
Maternal serum alpha-fetoprotein in normal pregnancy at 11-13 weeks' gestation.
Bredaki FE, Wright D, Akolekar R, Cruz G, Nicolaides KH.
Fetal Diagn Ther 2011;30:274-9. -
First-Trimester Screening for Trisomy 21 Using Alpha-Fetoprotein.
Bredaki FE, Wright D, Matos P, Syngelaki A, Nicolaides KH.
Fetal Diagn Ther 2011;30:215-8. -
Prediction of spontaneous preterm delivery from maternal factors, obstetric history and placental perfusion and function at 11-13 weeks.
Beta J, Akolekar R, Ventura W, Syngelaki A, Nicolaides KH.
Prenat Diagn 2011;31:75-83. -
Maternal serum a-fetoprotein at 11-13 weeks' gestation in spontaneous early preterm delivery.
Beta J, Bredaki FE, Calvo JR, Akolekar R, Nicolaides KH.
Fetal Diagn Ther 2011;30:88-93. -
Maternal serum progesterone-induced blocking factor at 11-13 weeks gestation in spontaneous early preterm delivery.
Beta J, Szekeres-Bartho J, Skyfta E, Akolekar R, Nicolaides KH.
Fetal Diagn Ther 2011;29:197-200. -
Maternal thyroid function at 11-13 weeks of gestation and spontaneous preterm delivery.
Ashoor G, Maiz N, Rotas M, Jawdat F, Nicolaides KH.
Obstet Gynecol 2011;117:293-8. -
First-trimester combined screening for trisomy 21 at 8-13 weeks.
Wright D, Spencer K, Kagan K, Tørring N, Petersen O, Christou A, Kallikas J, Nicolaides K.
Ultrasound Obstet Gynecol 2010;36:404-11. -
Synergy of Total PLAC4 RNA concentration and measurement of the RNA single-nucleotide polymorphism allelic ratio for the noninvasive prenatal detection of Trisomy 21.
Tsui NB, Akolekar R, Chiu RW, Chow KC, Leung TY, Lau TK, Nicolaides KH, Lo YM.
Clin Chem 2010;56:73-81. -
Epigenetic-genetic chromosome dosage approach for fetal trisomy 21 detection using an autosomal genetic reference marker.
Tong YK, Chiu RW, Akolekar R, Leung TY, Lau TK, Nicolaides KH, Lo YM.
PLoS One 2010;5:e15244. -
Two-stage first-trimester screening for trisomy 21 by ultrasound assessment and biochemical testing.
Kagan K, Staboulidou I, Cruz JJ, Wright D, Nicolaides K.
Ultrasound Obstet Gynecol 2010;36:542-7. -
Maternal plasma DNA analysis with massively parallel sequencing by ligation for noninvasive prenatal diagnosis of Trisomy 21.
Chiu RW, Sun H, Akolekar R, Clouser C, Lee C, McKernan K, Zhou D, Nicolaides KH, Lo YM.
Clin Chem 2010;56:459-63. -
First-trimester maternal serum matrix metalloproteinase-9 (MMP-9) and adverse pregnancy outcome.
Poon LC, Nekrasova E, Anastassopoulos P, Livanos P, Nicolaides KH.
Prenat Diagn 2009;29:553-9. -
Prospective validation of first-trimester combined screening for trisomy 21.
Kagan KO, Etchegaray A, Zhou Y, Wright D, Nicolaides KH.
Ultrasound Obstet Gynecol 2009;34:14-8. -
Effect of deviation of nuchal translucency measurements on the performance of screening for trisomy 21.
Kagan KO, Wright D, Etchegaray A, Zhou Y, Nicolaides KH.
Ultrasound Obstet Gynecol 2009;33:657-64. -
First-trimester ultrasound and biochemical markers of aneuploidy and the prediction of preterm or early preterm delivery.
Spencer K, Cowans NJ, Molina F, Kagan KO, Nicolaides KH.
Obstet Gynecol 2008;31:147-52. -
Screening for trisomy 21 in twin pregnancies in the first trimester: an update of the impact of chorionicity on maternal serum markers.
Spencer K, Kagan KO, Nicolaides KH.
Prenat Diagn 2008;28:49-52. -
First-trimester maternal serum a disintegrin and metalloprotease 12 (ADAM12) and adverse pregnancy outcome.
Poon LC, Chelemen T, Granvillano O, Pandeva I, Nicolaides KH.
Obstet Gynecol 2008;112:1082-90. -
Prenasal thickness in trisomy-21 fetuses at 16-24 weeks of gestation.
Persico N, Borenstein M, Molina F, Azumendi G, Nicolaides KH.
Ultrasound Obstet Gynecol 2008;32:751-4. -
Frontomaxillary facial angle in trisomy 21 fetuses at 16-24 weeks of gestation.
Molina F, Persico N, Borenstein M, Sonek J, Nicolaides KH.
Ultrasound Obstet Gynecol 2008;31:384-7. -
Screening for trisomy 21 by maternal age, fetal nuchal translucency thickness, free beta-human chorionic gonadotropin and pregnancy-associated plasma protein-A.
Kagan KO, Wright D, Baker A, Sahota D, Nicolaides KH.
Ultrasound Obstet Gynecol 2008;31:618-24.